Interestingly, this patient's tumor next-generation sequencing analysis showed a pathogenic mutation in KRAS G12R (seen in ∼20% of PC), which may have an impaired ability to activate PI3K-mTOR signaling.20 This evidence concerns the gene KRAS and neoplasm.